According to a new report published by Reports Monitor titled, “Oligonucleotide Synthesis Market by Component, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Oligonucleotide Synthesis market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025.
Oligonucleotide synthesis is referred to construction of nucleic acids such DNA and RNA with specific chemical structure or sequences. Oligonucleotides are predominantly used in laboratory applications such as diagnostic, therapeutic, research & development as well as industrial and academic. They are applied since initial research and screening until target validation and drug development. Forward movement made in recent years in contemporary solid phase based synthesis technologies have made possible the synthesis of automated high-through-put custom oligonucleotide.
Growing usage of synthesized oligonucleotides in molecular diagnostics and in clinical application as well as increasing emphasis on genetics & genomics has led the oligonucleotide synthesis market to propel in last couple of years. Moreover, successive improvements in synthesis procedures, amplification and automation have entirely transformed biological research leading the market to grow further. In addition, rising expenditure on R&D, increasing government investment and rise in venture capital funding is fuelling the growth of the market.
However, lack of consolidated set of guidelines for therapeutic oligonucleotides and price erosion of synthesized oligonucleotides may restraint the growth of the market. Swiftly growing healthcare sector leveraging oligonucleotides in research, therapeutics and diagnostics, huge investment by pharma and biotech companies and existence of key market players strongly supports the growth of the market in North America.
The global oligonucleotide synthesis market is segmented on the basis of product, application, end-user and region. Based on product type the market is differentiated into synthesized oligonucleotides, reagents and equipment’s. Synthesized oligonucleotides are further divided into primers, probes, linkers & adopters. Application wise the market is categorized into research, diagnostics and therapeutics.
Research is further separated into Sequencing, PCR, OPCR, gene synthesis and others. Therapeutics is segmented into nucleic acid aptamers, RNAi, DNA/antisense oligonucleotide and immunotherapy applications. Depending upon end-user the market is classified into pharmaceutical & biotechnological companies, diagnostic laboratories, academic research institutes and other end-users.
The global market for oligonucleotide synthesis appears to be highly fragmented in terms of competition. Partnership, product launch, and channel integration are some of the other strategies adopted by market players. Major players in the market of oligonucleotide synthesis are Sigma-Aldrich Corporation Thermo Fisher Scientific, Integrated DNA Technologies, Agilent Technologies, GE Healthcare, BioAutomation, Eurofins Genomics, GeneDesign, Eurogentec and GenScript.
In December 2016, Ajinomoto Co., Inc. acquired all shares of a major Japanese contract development and manufacturing organization GeneDesign, Inc. The company primarily engages nucleic acid drug production. After this acquisition Ajinomoto Co. has planned to create collaborations in order to accelerate expansion of the oligonucleotide manufacturing technologies and pharmaceutical manufacturing capabilities.
About Garner Insights:
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.